ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

被引：0
|
作者：
Zheng, Y. [1 ]
Lanitis, T. [2 ]
Ambavane, A. [2 ]
Proskorovsky, I [3 ]
Bharmal, M. [4 ]
Phatak, H. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Evidera, London, England
[3] Evidera, St Laurent, PQ, Canada
[4] Merck KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.108
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN26
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] ASSESSMENT OF CLINICAL VALUE IN ONCOLOGY: COMPARATIVE ANALYSIS OF VALUE FRAMEWORKS AND HTAS
    Niven, C.
    Hough, N. M.
    Zhou, A. Y.
    Qin, L.
    Alexander, R.
    VALUE IN HEALTH, 2016, 19 (07) : A754 - A754
  • [2] A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
    Hoxhaj, Ilda
    Govaerts, Laurenz
    Simoens, Steven
    Van Dyck, Walter
    Huys, Isabelle
    Gutierrez-Ibarluzea, Inaki
    Boccia, Stefania
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (21) : 1 - 21
  • [3] On value frameworks and opportunity costs in health technology assessment
    Booth, Neill
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (05) : 367 - 372
  • [4] Health technology assessment and value: the cancer value label (CAVALA) methodology
    Rocha-Goncalves, Francisco
    Borges, Marina
    Redondo, Patricia
    Laranja-Pontes, Jose
    ECANCERMEDICALSCIENCE, 2016, 10
  • [5] ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?
    Ambavane, A.
    Benedict, A.
    Rivolo, S.
    Rakonczai, P.
    Kapetanakis, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 671 - 671
  • [6] Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health
    Kim, Hansoo
    Goodall, Stephen
    Liew, Danny
    VALUE IN HEALTH, 2019, 22 (05) : 593 - 600
  • [7] USING DECISION MAKING CLINICAL SCENARIOS TO APPRAISE PREFERENCES AND VALUE JUDGMENTS IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
    Santoro Neto, L.
    Ferraz, M.
    VALUE IN HEALTH, 2015, 18 (07) : A520 - A520
  • [8] Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies
    Li, J.
    Vivot, A.
    Alter, L.
    Durand-Zaleski, I.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (04) : 405 - 409
  • [9] The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
    Sabine Elisabeth Grimm
    Mark Strong
    Alan Brennan
    Allan J. Wailoo
    PharmacoEconomics, 2017, 35 : 1287 - 1296
  • [10] The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
    Grimm, Sabine Elisabeth
    Strong, Mark
    Brennan, Alan
    Wailoo, Allan J.
    PHARMACOECONOMICS, 2017, 35 (12) : 1287 - 1296
12345